hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06343155, orgStudyIdInfo id: E-10840098-202.3.02-235, briefTitle: Effect of Chronic Low Back Pain Treatment on Temporomandibular Disorder", statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-11, primaryCompletionDateStruct date: 2024-05-27, completionDateStruct date: 2024-06-03, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Medipol University, class: OTHER, descriptionModule briefSummary: According to the information obtained from clinical studies, it has been stated that Temporomandibular Disorder (TMD) is associated with chronic low back pain (LBP). In this study, participants will be divided into two groups. Only Rocabado's exercise will be given to the Rocabado's group (RG), and Rocabado's and therapeutic lumbar exercises will be given to the therapeutic group (TG). Warm-up exercises will be given before starting the exercises with the therapeutic group, and cool-down exercises will be given after the exercises with the therapeutic group. At the end of the sixth week, the effect of therapeutic lumbar exercises on TMD pain and function will be evaluated., conditionsModule conditions: Temporomandibular Disorder, conditions: Chronic Low-back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: There are two groups: Therapeutic group and Rocabado's group., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Therapeutic Group, interventions name: Rocabado's Group, outcomesModule primaryOutcomes measure: Temporomandibular Joint Range of Motion Measurement (ROM), secondaryOutcomes measure: The Jaw Functional Limitation Scale 20 (JFLS-20), secondaryOutcomes measure: Oral Health Impact Profile - 14 (OHIP-14), otherOutcomes measure: The short-form McGill Pain Questionnaire (SF-MPQ), otherOutcomes measure: Graded Chronic Pain Scale 2.0 total (GCPS 2.0), otherOutcomes measure: Visual Analog Scale, eligibilityModule sex: ALL, minimumAge: 23 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul Medipol University, city: Istanbul, country: Turkey, contacts name: İkra Çakıcı, role: CONTACT, phone: +90 05426696487, email: ikrabayraktar951@gmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06343142, orgStudyIdInfo id: 42038, briefTitle: Effects of Time of Day and Nut Intake on Cognitive Performance, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Monash University, class: OTHER, descriptionModule briefSummary: This is a 2 x 2-factor crossover design study to investigate the effects of time of day and nuts on post-meal cognitive performance., conditionsModule conditions: Cognitive Performance, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: 2 x 2-factor crossover design study, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Nuts, interventions name: Nut-free meal, outcomesModule primaryOutcomes measure: N-back task - accuracy, primaryOutcomes measure: N-back task - matched responses, primaryOutcomes measure: N-back task - false alarm, primaryOutcomes measure: N-back task - reaction time, primaryOutcomes measure: Stroop test - congruent, primaryOutcomes measure: Stroop test - incongruent, primaryOutcomes measure: Stroop test - interference, secondaryOutcomes measure: Multitasking - pure blocks, secondaryOutcomes measure: Multitasking - mixed blocks, secondaryOutcomes measure: Multitasking - mixing cost, secondaryOutcomes measure: Satiety - hunger, secondaryOutcomes measure: Satiety - fullness, secondaryOutcomes measure: Satiety - satisfaction, secondaryOutcomes measure: Satiety - eating capacity, secondaryOutcomes measure: Satiety index, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Department of Nutrition, Dietetics and Food - Monash University, status: RECRUITING, city: Notting Hill, state: Victoria, zip: 3168, country: Australia, contacts name: Barbara R Cardoso, PhD, role: CONTACT, phone: +61499840472, email: barbara.cardoso@monash.edu, contacts name: Maxine Bonham, PhD, role: CONTACT, phone: +61418 234 292, email: maxine.bonham@monash.edu, geoPoint lat: -37.905, lon: 145.1427, hasResults: False
protocolSection identificationModule nctId: NCT06343116, orgStudyIdInfo id: BPL-Nim-CRC-3001, briefTitle: Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer, acronym: NOTABLE-308, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Biotech Pharmaceutical Co., Ltd., class: OTHER, descriptionModule briefSummary: This is a randomized, double-blind, placebo-controlled, multicenter study. The main purpose of the study is to evaluate the clinical efficacy and safety of nimotuzumab combined with trifluridine/tipiracil in third-line and beyond for the treatment of metastatic colorectal cancer (mCRC). This study planned to be divided into two parts: Part A and Part B. Part A (safety run-in) with a 3 + 3 study design, which primary endpoint is safety; Part B (main study) with a prospective, randomized, double-blind, placebo-controlled design, which primary endpoint is overall survival (OS)., conditionsModule conditions: Refractory Metastatic Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 420, type: ESTIMATED, armsInterventionsModule interventions name: Nimotuzumab injection, interventions name: Placebo, interventions name: Trifluridine/tipiracil, outcomesModule primaryOutcomes measure: overall survival (OS), primaryOutcomes measure: dose-limiting toxicity (DLT), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: time to progress (TTP), secondaryOutcomes measure: overall response rate (ORR), secondaryOutcomes measure: disease control rate (DCR), secondaryOutcomes measure: duration of response (DoR), secondaryOutcomes measure: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30), secondaryOutcomes measure: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29), secondaryOutcomes measure: Adverse Events, otherOutcomes measure: tumor-related markers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343103, orgStudyIdInfo id: IEO 1735, briefTitle: Study Evaluating Occupational Exposure to Antineoplastic Drugs, acronym: BRIC, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-02, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: The multicenter study involves comparing two groups (an exposed group and a control group). The exposed group is selected from workers who perform their activities in drug handling areas (DH) or units for antineoplastic preparation (UFA), while the control group involves the voluntary participation of non-exposed workers (administrative staff).The control group is selected based on the characteristics of the exposed group to ensure a homogeneous sample in terms of size and characteristics., conditionsModule conditions: Cytotoxicity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Workers exposed, interventions name: Workers not exposed, outcomesModule primaryOutcomes measure: Evaluation of the difference in micronuclei frequency, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Ospedale Policlinico San Martino, status: RECRUITING, city: Genova, country: Italy, contacts name: Sabrina Beltramini, role: CONTACT, geoPoint lat: 44.40478, lon: 8.94438, locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Emanuela Omodeo Salè, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, locations facility: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", status: RECRUITING, city: Napoli, country: Italy, contacts name: Piera Maiolino, role: CONTACT, geoPoint lat: 40.85216, lon: 14.26811, locations facility: Istituto Oncologico Veneto Irccs, status: RECRUITING, city: Padova, country: Italy, contacts name: Nicoletta Rigamonti, role: CONTACT, geoPoint lat: 45.40797, lon: 11.88586, locations facility: Fondazione Policlinico Universitario Campus Bio-Medico, status: RECRUITING, city: Roma, country: Italy, contacts name: Andrea Di Mattia, role: CONTACT, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06343077, orgStudyIdInfo id: STUDY-22-00106, briefTitle: Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-16, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Ashutosh Kumar Tewari, class: OTHER, collaborators name: Oncovir, Inc., descriptionModule briefSummary: This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance., conditionsModule conditions: Prostate Cancer Patients on Active Surveillance, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 114, type: ESTIMATED, armsInterventionsModule interventions name: Poly-ICLC intramuscular (IM) injection, interventions name: Poly-ICLC, Intertumoral (IT) injection, outcomesModule primaryOutcomes measure: Proportion of subjects without Gleason group upgrade after treatment, primaryOutcomes measure: Proportion of subjects without Gleason group upgrade after treatment, primaryOutcomes measure: Proportion of subjects without Gleason group downgrade after treatment, primaryOutcomes measure: Proportion of subjects without Gleason group downgrade after treatment, secondaryOutcomes measure: Number of subjects who experience adverse events per NCI-CTCAE 5.0, secondaryOutcomes measure: Number of subjects who experience adverse events per NCI-CTCAE 5.0, secondaryOutcomes measure: Number of subjects who receive prostate cancer treatment, secondaryOutcomes measure: Number of subjects who receive prostate cancer treatment, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Icahn School of Medicine at Mount Sinai (ISMMS), status: RECRUITING, city: New York, state: New York, zip: 10029, country: United States, contacts name: Monali Fatterpekar, PhD, role: CONTACT, email: monali.fatterpekar@mountsinai.org, contacts name: Sujit S Nair, PhD, role: CONTACT, phone: 212-241-7005, email: sujit.nair@mountsinai.org, contacts name: Ashutosh K Tewari, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06343064, orgStudyIdInfo id: PLB1001/PLB1004-NSCLC-Ib/II-01, briefTitle: Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-13, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Avistone Biotechnology Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC, conditionsModule conditions: Non-Small-Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: Vebreltinib, interventions name: PLB1004, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])., primaryOutcomes measure: Incidence of dose-limiting toxicities (DLT) as defined in the protocol., primaryOutcomes measure: Overall Response Rate (ORR）, secondaryOutcomes measure: Pharmacokinetics of Vebreltinib and PLB1004 : Area under the concentration time curve (AUC), secondaryOutcomes measure: Pharmacokinetics of Vebreltinib and PLB1004: Maximum plasma concentration of the study drug (C-max), secondaryOutcomes measure: Pharmacokinetics of Vebreltinib and PLB1004: Time to maximum plasma concentration of the study drug (T-max), secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Pulmonary Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200433, country: China, contacts name: Caichun Zhou, PHD, role: CONTACT, phone: +86-21-65115006, email: caicunzhoudr@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06343051, orgStudyIdInfo id: STUDY-23-01681, briefTitle: USCOM in Newly Diagnosed FGR Cases, acronym: USCOM FGR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Icahn School of Medicine at Mount Sinai, class: OTHER, descriptionModule briefSummary: The purpose of this research study is to study the use of an ultrasound measurement system (USCOM) for patients with newly diagnosed fetal growth restriction (FGR). This system uses a technology to measure how much blood is being pumped in and out of the heart, which is important for understanding the heart's function in relation to pregnancy., conditionsModule conditions: Fetal Growth Restriction, conditions: USCOM, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: USCOM, outcomesModule primaryOutcomes measure: Systemic vascular resistance obtained from USCOM, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mount Sinai Hospital, city: New York, state: New York, zip: 10029, country: United States, contacts name: Nicola F Tavella, MPH, role: CONTACT, phone: 212-241-3888, email: nicola.tavella@mssm.edu, contacts name: Rachel J Meislin, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06343025, orgStudyIdInfo id: Hasan Kalyoncu University, briefTitle: The Effects of Tai Chi and Pilates for Individuals With Prediabetes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Nigde Omer Halisdemir University, class: OTHER, collaborators name: Hasan Kalyoncu University, descriptionModule briefSummary: The purpose of this study; To investigate the effects of Clinical Pilates and Tai Chi exercises on glycemic control, body composition, balance function and physical activity level in individuals with prediabetes., conditionsModule conditions: PreDiabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Individuals will be divided into 3 groups: Clinical Pilates group, Tai Chi group and Control group. 3 groups. 3 groups will be measured at the same time and then the exercise part will begin., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Outcomes ,Assesor, who will make the evaluations in the first week and after 12 weeks, will not know which group the people are in., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Pilates Exercises Group, interventions name: Tai Chi Exercises Group, outcomesModule primaryOutcomes measure: Glisemic Control, primaryOutcomes measure: Body Composition, primaryOutcomes measure: Balance, primaryOutcomes measure: Physical Activity Level, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343012, orgStudyIdInfo id: 0305900, briefTitle: Caring Leadership Intervention Program for First-Line Nurse Managers, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2022-12-31, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Matrouh University, class: OTHER, descriptionModule briefSummary: Caring leadership can help first-line nurse managers create a healthy environment, resulting in a positive outcome for nurse staff, patients, and healthcare organizations., conditionsModule conditions: Intervention, conditions: Behavior, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A quasi-experimental study design utilized two groups, study and control groups, primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: A quasi-experimental study design utilized two groups, study and control groups., whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Caring leadership Intervention program, outcomesModule primaryOutcomes measure: Questionnaire to measure first-line nurse managers' knowledge, primaryOutcomes measure: Questionnaire to measure the managerial actions of first-line nurse managers, primaryOutcomes measure: Questionnaire to assess nurses' perceived first-line nurse managers' caring behavior, primaryOutcomes measure: questionnaire to measure nurse outcomes, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Nursing, Matrouh University, city: Marsa Matruh, zip: 002, country: Egypt, geoPoint lat: 31.3529, lon: 27.23725, hasResults: False
protocolSection identificationModule nctId: NCT06342999, orgStudyIdInfo id: 22-012399, briefTitle: Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2035-07, completionDateStruct date: 2035-07, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Mauro H. Schenone, class: OTHER, descriptionModule briefSummary: The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS)., conditionsModule conditions: Hypoplastic Left Heart Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Fetal Aortic Valvuloplasty Procedure, interventions name: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter, interventions name: Trek RX and Mini Trek RX Coronary Dilatation Catheter, outcomesModule primaryOutcomes measure: Number of cases in which the procedure was successful, primaryOutcomes measure: Number of cases in which a biventricular repair was achieved, primaryOutcomes measure: Number cases with pulmonary hypertension, secondaryOutcomes measure: Number of cases delivered prematurely, secondaryOutcomes measure: Number of cases with perinatal death, secondaryOutcomes measure: Number of maternal complications, eligibilityModule sex: FEMALE, maximumAge: 45 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False